BMRN Shorts Build as Analysts Trim Targets Post-Earnings

BioMarin Pharmaceutical finds itself in an uncomfortable position this week: short sellers have been adding steadily even as a broad analyst consensus insists the stock is worth far more than its current price.

The short interest story is the week's clearest tension. Bears have been building positions for over a month. At 6.6% of free float, short interest has risen 27.7% over the past 30 days, with most of that build concentrated from early October onward. Shares shorted climbed from roughly 10 million at the start of October to 12.7 million by November 3. That is a meaningful accumulation in a short period. The borrow market, however, offers no support for a squeeze narrative. Availability remains extraordinarily loose, with over 150 million shares available to borrow against roughly 12.7 million shorted, an availability ratio of around 1,755%. Cost to borrow is just 0.42%, near the low for the period. The lending market is not under any stress, and there is no mechanical pressure on short sellers to cover. Options positioning also points to a call-heavy stance rather than defensive hedging. The put/call ratio of 0.30 is marginally below its 20-day average and sits near the 52-week low of 0.28, suggesting that while shorts are building, the broader options market is not particularly worried about the downside.

The earnings print on November 2 is the catalyst behind the analyst activity that followed. JP Morgan's Jessica Fye and Morgan Stanley's Matthew Harrison, both bellwether names, trimmed targets within 24 hours of the report while keeping Overweight ratings intact. Morgan Stanley cut from $122 to $119, JP Morgan from $87 to $86. Oppenheimer, RBC Capital and Stifel also lowered targets, though none changed their directional rating. The collective message from the Street is that the quarter disappointed on some metric but not enough to shift the fundamental thesis. The mean target still sits at $91.04 against a close of $55.66, implying roughly 63% upside from current levels. That is a wide gap, and it reflects genuine disagreement about how quickly competitive pressure in achondroplasia translates into revenue attrition. The bull case rests on VOXZOGO's Phase 3 CANOPY-HCH-3 data, which showed a 2.33 cm per year placebo-adjusted annualised growth velocity benefit, an sNDA already filed, and royalty income from the Ascendis settlement running through May 2030. The bear case centres on the competitive threat from YUVIWEL's weekly dosing in infants, noting that over half of US VOXZOGO new starts in Q2 2026 were children under two, the most substitution-vulnerable cohort. BioMarin also carries an estimated $3.5 billion of debt against roughly $1.9 billion in cash by end-Q3 2027, which limits the buffer for execution risk.

Factor scores sharpen the contrast. BioMarin ranks in the 97th percentile on EPS surprise and in the 99th percentile for 12-month forward earnings growth year-on-year, reflecting how sharply consensus has reset. The analyst recommendation differential also ranks in the 97th percentile, consistent with the wide gap between current price and mean target. At the same time, the 30-day EPS momentum score has dropped to the 16th percentile, meaning near-term estimate revisions have turned negative. The stock's EV/EBITDA of 7.3x and PE of 9.5x are not demanding multiples, and earnings yield ranks in the 86th percentile. The valuation is not the problem. The problem, as reflected in both the month-long short build and the downward revision cycle, is uncertainty about the trajectory of the core VOXZOGO franchise.

Retail attention, as measured by Wikipedia page views, is running at a z-score of 2.44 against BioMarin's own 90-day history, the highest attention reading in the dataset. That spike coincides with the earnings release and the Phase 3 data, not an unusual pattern for a binary-data biotech event, but it shows the stock is drawing more eyes than normal. Among correlated peers, the week was broadly positive: VRTX gained 1.9% and ACAD added 2.0%, while BNTC slipped 3.2%. BioMarin's 0.6% weekly gain was modest but kept it in positive territory alongside most of the group, even after falling 3.1% on November 3 alone following the earnings print.

The stock's short score of 46.9 places it squarely in the middle of the ORTEX universe, neither extreme. What to watch next is whether the short build continues to grind higher through November or stabilises now that the earnings event has passed, and whether the Street's wide spread between current price and target begins to narrow as VOXZOGO competitive data from Ascendis and others accumulates ahead of the next print, scheduled for February 19, 2027.